Combination Antibiotics Show Trend Toward Faster Stability in Pneumonia Sepsis

Patients with sepsis caused by community-acquired pneumonia reached clinical stability slightly faster when treated empirically with a beta-lactam antibiotic combined with a macrolide or doxycycline rather than a beta-lactam alone, according to a retrospective cohort study conducted at Zhejiang Xiaoshan Hospital in Hangzhou, China. The difference, however, did not reach statistical significance, and the authors present the finding as a signal that warrants larger prospective testing rather than as proof of superiority.

Community-acquired pneumonia complicated by sepsis remains one of the most demanding infectious syndromes in acute care, carrying substantial morbidity, mortality, and healthcare burden. Clinical guidelines widely recommend beta-lactam-based combination therapy for severe pneumonia, yet the optimal empirical regimen for septic pneumonia specifically has remained uncertain. Clinicians face a persistent balancing act: starting early treatment broad enough to cover likely pathogens while avoiding unnecessary broad-spectrum antibiotic use that fuels antimicrobial resistance. Evidence directly addressing this high-risk population has been limited, which motivated the analysis.

The study enrolled adult patients admitted between January 2021 and January 2025 who had community-acquired pneumonia-associated sepsis and received empirical therapy within 48 hours of admission. Patients were assigned to one of two strategies: beta-lactam monotherapy, or beta-lactam-based combination therapy with a macrolide or doxycycline. Before statistical matching, 100 patients were included; after 1:1 propensity score matching, which paired patients with comparable baseline characteristics, 80 patients remained for analysis.

The primary outcome was time to clinical stability (TTCS). Secondary outcomes included mortality, length of hospital stay, antibiotic duration, changes in Sequential Organ Failure Assessment (SOFA) scores, inflammatory biomarkers, clinical cure, and adverse events. Time to clinical stability was analyzed with Kaplan-Meier curves and Cox proportional hazards regression.

Median time to clinical stability was 5.0 days in the monotherapy group and 4.0 days in the combination therapy group, a one-day difference that was not statistically significant (P=0.129). Combination therapy also showed favorable trends in hospitalization duration, clinical cure, reduction of inflammatory markers, and recovery of organ function, though the reported results did not establish statistically significant differences for these outcomes in this sample.

The investigators adjusted for admission SOFA score in their regression model. After this adjustment, combination therapy showed a nonsignificant trend toward earlier clinical stability, with an adjusted hazard ratio of 1.42 (95% confidence interval 0.88-2.29; P=0.151). A hazard ratio above 1 indicates a higher probability of reaching stability at any given time, but the confidence interval crossing 1.0 means the data cannot rule out no difference.

No significant increase in adverse events was observed in the cohort, an observation the authors report alongside the favorable but nonsignificant efficacy trends.

The authors conclude that in patients with community-acquired pneumonia-associated sepsis, beta-lactam-based combination therapy showed a trend toward earlier clinical stability than beta-lactam monotherapy, although the difference was not statistically significant. They frame the work as addressing an important evidence gap in septic pneumonia management and as supporting further investigation of individualized antimicrobial strategies guided by disease severity and biological characteristics, an approach aligned with the broader push toward precision antimicrobial management.

The interpretation carries important caveats that the authors themselves emphasize. The retrospective, single-center design means treatment assignment reflected real-world clinical practice rather than randomization, and unmeasured differences between patients could influence outcomes even after propensity matching. The relatively small sample size of 80 matched patients limits statistical power, so a true moderate benefit of combination therapy could plausibly have produced the observed pattern without reaching significance. The authors state that these limitations should be considered when interpreting the findings, and the results support larger, ideally prospective, studies before any change to empirical prescribing practice for septic pneumonia.

Subject of Research: Clinical outcomes of empirical antibiotic strategies in community-acquired pneumonia-associated sepsis: a propensity score-matched cohort study

Article Title: Clinical outcomes of empirical antibiotic strategies in community-acquired pneumonia-associated sepsis: a propensity score-matched cohort study

Article References: Ding, L., Hu, R., & Ying, Y. (2026). Clinical outcomes of empirical antibiotic strategies in community-acquired pneumonia-associated sepsis: a propensity score-matched cohort study. Frontiers in Cellular and Infection Microbiology, 16, Article 1979459. https://doi.org/10.3389/fcimb.2026.1979459

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1979459

Keywords: Clinical, outcomes, empirical, antibiotic, strategies, community-acquired, pneumonia-associated, sepsis, propensity, score-matched, cohort, scientific research